
Highlights
Capital Markets Day – May 25, 2023
As part of the event, we presented and discussed Fresenius Kabi’s role as Operating Company, elaborated on its “Vision 2026” in more detail and provided in-depth information on the company’s operating businesses and growth prospects.
Presenters: Michael Sen, CEO of Fresenius and Pierluigi Antonelli, CEO of Fresenius Kabi and his management team
A Replay of the Webcast is availalble.


“With a simplified Group structure, improved performance, and a clear focus, Fresenius’s course is set. Productivity measures are gaining traction and we’ve started the new year with good growth momentum. Our Operating Companies Fresenius Kabi and Fresenius Helios both had strong first quarter performance. The deconsolidation of Fresenius Medical Care is on track and the turnaround is also progressing. We want to accelerate this momentum.”
Michael Sen, Chairman of the Management Board
Financial Highlights Q1/23
Revenue
€ 10225 m
+5% 1
Q1/22: €9,720 m
NET INTEREST 2
€ -170 m
-41% 1
Q1/22: € -119 m
EBIT 2
€ 908 m
-11% 1
Q1/22: €1,000 m
Employees
313812
Dec. 31, 2022: 316,920
Net income 2, 3
€ 389 m
-17% 1, 2
Q1/22: €463 m
Earning per share 2, 3
€ 0.69
-18% 1, 2
Q1/22: €0.83
1 In constant currency
2 Before special items
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA